Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 18/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.35 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30480247 | 0.86 | AHCY (0.44) | ADORA3ADORA1ADORA2API4KAPI4K2B | |
| SCHEMBL29574515 | 0.82 | ADORA3 (0.40) | ADORA3ADORA1ADORA2A | |
| SCHEMBL30480248 | 0.81 | ADORA3 (0.41) | ADORA3ADORA1ADORA2A | |
| SCHEMBL15935852 | 0.79 | ADORA3 (0.47) | ADORA3ADORA1ADORA2A | |
| SCHEMBL12509356 | 0.79 | ADORA3 (0.47) | ADORA3ADORA1ADORA2A | |
| SCHEMBL23201580 | 0.79 | ADORA3 (0.47) | ADORA3ADORA1ADORA2A | |
| SCHEMBL29573444 | 0.79 | ADORA3 (0.47) | ADORA3ADORA1ADORA2A | |
| SCHEMBL30480242 | 0.77 | PI4KA (0.56) | ADORA3ADORA1ADORA2API4KAPI4K2B | |
| SCHEMBL12509206 | 0.77 | ADORA3 (0.40) | ADORA3ADORA1ADORA2A | |
| SCHEMBL15935848 | 0.77 | ADORA3 (0.40) | ADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4196219-A1 | A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE | Biointervene, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022040241-A1 | A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE | BIOINTERVENE, INC. (US) | 2022-02-24 | — | — | WO | disclosed |